Sharemaestro company-news research for Immunitybio Inc (IBRX), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest IBRX news and sentiment
Immunitybio Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
50 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone60/100
→
Published 30-day score52/100
Latest source headline
IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat
Stocktwits · 07 Oct 2026 03:27
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
50 current stories are mapped specifically to IBRX.
The score uses 9 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.254.
Confidence is 23/100, below the threshold for a firm score.
52/100
News scoreEarly balanced news score
23/100
Confidencethin evidence
100%/100
Company news50 company stories
87/100
Story agreement13/100 difference
News history
Daily score and story count over 30 days
16 Sep01 Oct15 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence5
0.254 after freshness weightingSource breadth100
9 independent publishersCompany relevance100
share tied directly to this companyFreshness12
recency-weighted evidenceAgreement87
how closely stories agreePublisher mix62
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202658USD 10.51+2.2%
02 Oct 202659USD 10.285+21.9%
25 Sep 202653USD 8.44-0.5%
18 Sep 202647USD 8.48+7.2%
11 Sep 202652USD 7.91-2.1%
04 Sep 202651USD 8.08+0.4%
28 Aug 202653USD 8.05+3.3%
21 Aug 202657USD 7.79+2.9%
Provisional evidence
News subjects
What is shaping the score
Market update5029 stories · 58%
Earnings5211 stories · 22%
Analyst action704 stories · 8%
Balance sheet642 stories · 4%
Regulatory and legal412 stories · 4%
Guidance502 stories · 4%
Source mix
Where the evidence comes from
Stocktwits5521 stories · 42%
StocksToTrade643 stories · 6%
The Cryptonomist642 stories · 4%
AD HOC NEWS562 stories · 4%
Insider Monkey552 stories · 4%
TradingKey522 stories · 4%
Stock Titan502 stories · 4%
Recurring subjects
Subjects appearing most often
Life Sciences23Financial Markets21Earnings11Finance5Immunotherapy3Biotech3Revenue Growth2Blockchain2Technology1Shareholder1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
07 Aug50 neutral15 Oct 07:21
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 15 Oct 07:21 | 55 | -4 | 25/100 (-15) | 50 (-11) | Provisional |
| 07 Oct 23:59 | 59 | +3 | 40/100 (+2) | 61 (+1) | Measured |
| 06 Oct 23:59 | 56 | -2 | 38/100 (+1) | 60 (+3) | Measured |
| 05 Oct 23:59 | 58 | +0 | 37/100 (-4) | 57 (-2) | Measured |
| 04 Oct 23:59 | 58 | -1 | 41/100 (-6) | 59 (+1) | Measured |
| 02 Oct 23:59 | 59 | +1 | 47/100 (+6) | 58 (+7) | Measured |
| 01 Oct 23:59 | 58 | +0 | 41/100 (-2) | 51 (-1) | Measured |
| 30 Sep 23:59 | 58 | +3 | 43/100 (+11) | 52 (+8) | Measured |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 50 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Balance sheet2 stories
0.0%56.1%
Analyst action4 stories
0.0%18.2%
Regulatory and legal1 story
9.7%0.0%
Market update12 stories
4.8%3.6%
Earnings2 stories
0.0%7.7%
Each side uses the same scale: 0–56.1% of the retained directional evidence.
Where the influence comes from
56.5%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
EarningsNot used in direction
ImmunityBio Inc Revenue Breakdown – HAN:26CA
ImmunityBio Inc (HAN:26CA) generated 96.46 million EUR in revenue last year, primarily from its Immunotherapies segment. The United States was the largest contributor to this revenue, accounting for 96.22 million EUR. This represents a significant increase from the previous year's figures…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ImmunityBio Inc (HAN:26CA) generated 96.46 million EUR in revenue last year, primarily from its Immunotherapies segment. The United States was the largest contributor to this revenue, accounting for 96.22 million EUR. This represents a significant increase from the previous year's figures of 14.24 million EUR for Immunotherapies and 13.73 million EUR from the US.
- Published
- 29 Sep 2026 13:23
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
—Unscored
EarningsNot used in direction
Dow, S&P 500, Nasdaq Futures Rise As Investors Shrug Off Fed Hold, Big Tech Earnings: IBRX, MSFT, SOFI, META In Focus
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 29 Sep 2026 02:29
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
57/100 tone
0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 29 Sep 2026 01:23
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- 0.1% of directional evidence · 16.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 28 Sep 2026 23:38
- News subject
- Market update
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 28 Sep 2026 21:34
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 26 Sep 2026 21:17
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for ImmunityBio Inc. (IBRX) stock, showing its current price and daily change. It also includes information on analyst ratings (currently unavailable) and earnings (no information provided). The article is presented within a trading education plat…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This page provides live quotes and charts for ImmunityBio Inc. (IBRX) stock, showing its current price and daily change. It also includes information on analyst ratings (currently unavailable) and earnings (no information provided). The article is presented within a trading education platform, cautioning readers about the risks and low profitability rates associated with day trading.
- Published
- 26 Sep 2026 13:22
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Is ImmunityBio (IBRX) A Bargain As Turkey Expansion Fuels Fresh Growth Hopes?
ImmunityBio (IBRX) shares climbed nearly 10% following its founder’s meeting with the Turkish President, signaling expansion into Turkey’s cancer care market. Despite a recent cool-off in momentum, the company's valuation storyline pegs its fair value at $13 per share, significantly above…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ImmunityBio (IBRX) shares climbed nearly 10% following its founder’s meeting with the Turkish President, signaling expansion into Turkey’s cancer care market. Despite a recent cool-off in momentum, the company's valuation storyline pegs its fair value at $13 per share, significantly above its current trading price of $8.64, driven by ambitious expectations for its cancer and immunology pipeline and global expansion of ANKTIVA. The article explores whether the current price fairly reflects ImmunityBio's story, considering both its growth potential and inherent risks.
- Published
- 25 Sep 2026 09:26
- News subject
- Market update
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
EarningsNot used in direction
ImmunityBio, Inc. (IBRX) Stock Price, News, Quote & History
This article provides a comprehensive overview of ImmunityBio, Inc. (IBRX), a biotechnology company focused on immunotherapies for cancer and infectious diseases. It details the company's stock performance, key financial metrics, earnings trends, analyst ratings, and product pipeline, inc…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a comprehensive overview of ImmunityBio, Inc. (IBRX), a biotechnology company focused on immunotherapies for cancer and infectious diseases. It details the company's stock performance, key financial metrics, earnings trends, analyst ratings, and product pipeline, including its FDA-approved drug Anktiva. The information is current as of September 25, 2026, with financial data up to Q2 FY26.
- Published
- 24 Sep 2026 16:26
- News subject
- Earnings
- Why this score
- Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
ImmunityBio Advances Patient-Centric Clinical Trial Design in Bladder Cancer
ImmunityBio, Inc. participated in the World Bladder Cancer Patient Forum 2026 in Hong Kong to advocate for patient-centric clinical trial design in bladder cancer. Anjali Malhotra from ImmunityBio joined a panel to discuss the importance of involving patients in research development. This…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ImmunityBio, Inc. participated in the World Bladder Cancer Patient Forum 2026 in Hong Kong to advocate for patient-centric clinical trial design in bladder cancer. Anjali Malhotra from ImmunityBio joined a panel to discuss the importance of involving patients in research development. This initiative highlights the company's commitment to advancing bladder cancer care and advocacy globally.
- Published
- 23 Sep 2026 18:44
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
ImmunityBio, Inc. Tokenized Stock (Robinhood) to Euro Price Today | Live IBRX to EUR Converter & Exchange Rate
This article from CryptoRank.io discusses the current lack of a live exchange rate for ImmunityBio, Inc. Tokenized Stock (Robinhood) (IBRX) to Euro (EUR). It notes that no price data is available, likely due to the cryptocurrency not being traded or having very low trading volume. The art…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article from CryptoRank.io discusses the current lack of a live exchange rate for ImmunityBio, Inc. Tokenized Stock (Robinhood) (IBRX) to Euro (EUR). It notes that no price data is available, likely due to the cryptocurrency not being traded or having very low trading volume. The article also touches on various factors that could affect the token's price once it becomes active.
- Published
- 23 Sep 2026 12:44
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BlockchainFinancial MarketsLife Sciences
74/100 tone
ImmunityBio Inc. (IBRX) shares jumped 9.94% after its founder, Dr. Patrick Soon-Shiong, met with Turkish President Recep Tayyip Erdogan, sparking optimism about the company's planned expansion into Turkey. This expansion follows the FDA approval and international acceptance of its immunot…
<0.1% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
ImmunityBio Inc. (IBRX) shares jumped 9.94% after its founder, Dr. Patrick Soon-Shiong, met with Turkish President Recep Tayyip Erdogan, sparking optimism about the company's planned expansion into Turkey. This expansion follows the FDA approval and international acceptance of its immunotherapy drug Anktiva in 34 countries. The company also reported strong Q2 revenues, nearly doubling year-over-year, and increased institutional investor conviction.
- Published
- 22 Sep 2026 20:26
- News subject
- Market update
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- <0.1% of directional evidence · 22.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode
ImmunityBio (IBRX) shares saw a surge after founder Patrick Soon-Shiong hinted at Nant's upcoming venture into blockchain-based stock trading, leading to speculation among retail traders that IBRX could become a tokenized stock. This speculation is fueled by the SEC's new "Innovation Exem…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ImmunityBio (IBRX) shares saw a surge after founder Patrick Soon-Shiong hinted at Nant's upcoming venture into blockchain-based stock trading, leading to speculation among retail traders that IBRX could become a tokenized stock. This speculation is fueled by the SEC's new "Innovation Exemption" which provides a five-year pathway for trading tokenized U.S.-listed securities. Nant is actively building a comprehensive blockchain trading platform to facilitate this new form of capital market.
- Published
- 21 Sep 2026 12:44
- News subject
- Market update
- Why this score
- Positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 3 consolidated
BlockchainFinancial MarketsLife SciencesTechnology
57/100 tone
1.5% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 19 Sep 2026 21:30
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 1.5% of directional evidence · 25.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
71/100 tone
0.2% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 19 Sep 2026 19:56
- News subject
- Analyst action
- Why this score
- Positive analyst conviction, Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- 0.2% of directional evidence · 25.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 19 Sep 2026 18:33
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 19 Sep 2026 10:45
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.1d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
ImmunityBio IBRX shares soared 7% in the last trading session to close at $8.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.7% loss over the past four weeks. Recently, ImmunityBio's founder and executive…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ImmunityBio IBRX shares soared 7% in the last trading session to close at $8.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.7% loss over the past four weeks. Recently, ImmunityBio's founder and executive chairman, Dr. Patrick Soon-Shiong, through his investment vehicle Nant Capital, led an $11.3 million PIPE financing for small-cap biotech PDS Biotechnology. Alongside the financing, a Nant affiliate received a one-year exclusive right to negotiate a license for PDS0101, PDS's investigational HPV-targeted immu
- Published
- 18 Sep 2026 07:41
- News subject
- Market update
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.2d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
BiotechEarningsEarnings EstimateImmunotherapyMedicalRevenue Growth
25/100 tone
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ImmunityBio, Inc. (IBRX) for potential corporate wrongdoing. The firm encourages shareholders who purchased ImmunityBio securities before January 19, 2026, and still hold them, to join the investigation. Bronstein, Gewi…
9.8% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ImmunityBio, Inc. (IBRX) for potential corporate wrongdoing. The firm encourages shareholders who purchased ImmunityBio securities before January 19, 2026, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital.
- Published
- 17 Sep 2026 21:37
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 54/100
- 30-day weight
- 9.8% of directional evidence · 27.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
Market updateNot used in direction
ImmunityBio (IBRX) Moved, So What Is Drawing Fresh Attention?
Nant Capital's investment of up to $22.3 million in a PIPE into PDS Biotech, along with Patrick Soon Shiong's new board seat there, pushed ImmunityBio (NasdaqGS:IBRX) up 6% on Monday and sharpened focus on his broader immunotherapy plans. ImmunityBio's share price has cooled slightly in t…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Nant Capital's investment of up to $22.3 million in a PIPE into PDS Biotech, along with Patrick Soon Shiong's new board seat there, pushed ImmunityBio (NasdaqGS:IBRX) up 6% on Monday and sharpened focus on his broader immunotherapy plans. ImmunityBio's share price has cooled slightly in the very short term, with a 1-day share price return of 2.75% and a 7-day share price return of 1.81%. However, the 30-day and 90-day share price returns of 7.53% and 16.45% suggest momentum is still building after a very large year-to-date share price gain of 302.97% and a 1-year total shareholder return of 18
- Published
- 16 Sep 2026 02:12
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.4d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
Balance SheetBiotechImmunotherapyRevenue GrowthShare PriceShareholder
Earlier company news
IBRX news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 96 older IBRX headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to IBRX, but the headline and available text are not mainly about Immunitybio Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of IBRX sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.